Accessible text: pCPA Dashboard

Accessible text for the pCPA February 2025 Dashboard

Data effective: December 31, 2024

For questions regarding this report, please contact: [email protected]

Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA’s inception, 638 negotiations have reached a letter of intent (LOI), including:

  • 235 for oncology
  • 64 for biosimilars
  • 74 for expensive drugs for rare diseases (EDRD)
Data for stacked line graph: Letters of intent

Oct 2024

MonthBiosimilarEDRDOther non-oncologyOther oncology
Aug 20120020
Sep 20120021
Oct 20120031
Nov 20120031
Dec 20120031
Jan 20130031
Feb 20130031
Mar 20130031
Apr 20130041
May 20130052
Jun 20130062
Jul 20130062
Aug 20130083
Sep 20130095
Oct 20130297
Nov 201302109
Dec 2013021110
Jan 2014021111
Feb 2014021114
Mar 2014021215
Apr 2014021216
May 2014021417
Jun 2014021417
Jul 2014031419
Aug 2014031621
Sep 2014041722
Oct 2014041922
Nov 2014052022
Dec 2014052022
Jan 2015052022
Feb 2015052323
Mar 2015052823
Apr 2015053125
May 2015053625
Jun 2015053826
Jul 2015054027
Aug 2015054228
Sep 2015054428
Oct 2015054629
Nov 2015054630
Dec 2015154632
Jan 2016154932
Feb 2016155032
Mar 2016155233
Apr 2016165533
May 2016165933
Jun 2016166034
Jul 2016166135
Aug 2016166236
Sep 2016176436
Oct 2016196538
Nov 20162106639
Dec 20162106739
Jan 20173106839
Feb 20173106843
Mar 20173107543
Apr 20173108043
May 20173108143
Jun 20173118146
Jul 20174118350
Aug 20175118451
Sep 20175118454
Oct 20175118455
Nov 20176128655
Dec 20176138860
Jan 20186149263
Feb 20186159364
Mar 20186159764
Apr 20186159865
May 20186169965
Jun 20186179966
Jul 201861810067
Aug 201871910470
Sep 201872210970
Oct 201872311270
Nov 201872311470
Dec 201872611773
Jan 201972612275
Feb 201972612278
Mar 201982612879
Apr 201982612984
May 201982613185
Jun 201982613385
Jul 201982713685
Aug 201992813986
Sep 2019102814190
Oct 2019112814492
Nov 2019132814694
Dec 2019142815497
Jan 2020142815597
Feb 2020142915598
Mar 20201531156100
Apr 20201531158101
May 20201633160107
Jun 20201633160107
Jul 20201934160108
Aug 20202034163111
Sep 20202034163112
Oct 20202134163113
Nov 20202136164115
Dec 20202237165117
Jan 20212237176118
Feb 20212737178119
Mar 20212738182121
Apr 20212838182122
May 20213038182124
Jun 20213138183125
Jul 20213140184125
Aug 20213140185127
Sep 20213340189132
Oct 20213442193132
Nov 20213643194136
Dec 20213643197137
Jan 20223643199141
Feb 20223744199144
Mar 20223845200150
Apr 20224146204151
May 20224146206152
Jun 20224646206155
Jul 20224647207156
Aug 20224648207158
Sep 20224649213161
Oct 20224651215162
Nov 20224654215165
Dec 20224855217168
Jan 20234855218171
Feb 20234956221171
Mar 20234957221171
Apr 20235158223184
May 20235160227184
Jun 20235260228195
Jul 20235261230197
Aug 20235362231199
Sep 20235462233200
Oct 20235462236201
Nov 20235665237204
Dec 20235665239206
Jan 20245666242207
Feb 20245768245207
Mar 20245868246210
Apr 20245868247211
May 20245869253211
Jun 20246070256213
Jul 20246170256214
Aug 20246170260220
Sep 20246170261226
Oct 20246171263228
Nov 20246172267232
Dec 20246474267235

Savings

Lower drug costs

pCPA activities saved jurisdictions an estimated $4.63B in 2023-24.

  • $3.72B from brand name drugs
  • $914M from generic drugs
  • Since 2010, cumulative savings are estimated to be $24.0B
Data for stacked bar chart: Savings
Fiscal YearBrand name drugsGeneric drug negotiationsTotal
FY 16/17$947,007,363$355,000,000$1,302,007,363
FY 17/18$1,263,644,399$740,000,000$2,003,644,399
FY 18/19$1,539,331,475$740,000,000$2,279,331,475
FY 19/20$1,847,496,049$740,000,000$2,587,496,049
FY 20/21$2,185,315,806$740,000,000$2,925,315,806
FY 21/22$2,667,069,216$750,000,000$3,417,069,216
FY 22/23$3,142,207,211$750,000,000$3,892,207,211
FY 23/24$3,715,798,849$913,979,661$4,629,778,510

HTA and pCPA volumes

  • 2024 saw a very high number of HTA recommendations, almost matching the record set in 2022.
  • The pCPA hired additional staff to increase its capacity to start new negotiations, and engaged 98 files in 2024.
Data for bar charts: HTA and PCPA volumes

Three bar charts tracking number of CDA recommendations issued, pCPA files engaged, and pCPA files closed, with 2024 projections shown as a stacked bar.

YearCDA recommendations issuedpCPA files engagedpCPA files closed
2015654341
2016645138
2017476168
2018627364
2019637582
2020577068
2021658574
2022828390
2023618193
2024799877

pCPA activity

  • The number of files in consideration fell below 20 files for the first time in the post-COVID era, due in part to increased staffing.
  • The pCPA is committed to further decreasing the queue over time.
  • Active negotiations have significantly increased, with the pCPA negotiating more than 40 files between September 15 and December 31, 2024.
Data for line graphs: pCPA activity 

Two line graphs:

  • Files under consideration: HTA recommendation to pCPA engagement
  • Active negotiations: pCPA engagement to LOI
MonthFiles under consideration (average)Active Negotiations (average)
Apr 20161922.25
May 201619.623.2
Jun 201619.525.75
Jul 201616.831
Aug 20161934.5
Sep 201621.7538
Oct 201623.233.8
Nov 201625.2538.5
Dec 20162741.75
Jan 201725.841.6
Feb 20172338
Mar 201722.7531.75
Apr 201725.232.2
May 20172341
Jun 201722.7543
Jul 201720.842.4
Aug 20171848
Sep 201714.2547.75
Oct 201713.849.6
Nov 201715.545.5
Dec 201718.840
Jan 201818.535
Feb 201822.535.75
Mar 201823.537.5
Apr 201825.240.4
May 201827.2545.25
Jun 201828.543.5
Jul 201828.445.4
Aug 201823.547.25
Sep 201822.249.4
Oct 20181653.25
Nov 201816.2554.25
Dec 201813.249
Jan 20191344.75
Feb 201914.7542.75
Mar 201912.241.6
Apr 201910.543.75
May 20191044
Jun 201913.246.4
Jul 201910.2548.5
Aug 20199.2547.25
Sep 20198.646.6
Oct 20195.2545.25
Nov 20195.7541
Dec 2019934.2
Jan 20201031.75
Feb 202010.531.75
Mar 202011.632
Apr 202015.2527.5
May 202020.820.8
Jun 202023.7526.5
Jul 202021.542.25
Aug 202023.244.6
Sep 20202444.5
Oct 202023.7544.25
Nov 202022.445.4
Dec 202025.542
Jan 202128.433
Feb 20212732.75
Mar 202125.2534.75
Apr 202126.2533.25
May 202129.233
Jun 202128.2534.75
Jul 202128.543
Aug 202129.444.2
Sep 20213439.25
Oct 202135.235.8
Nov 20212841.25
Dec 20212345.75
Jan 20222543
Feb 202228.2542.75
Mar 202231.543.5
Apr 202232.2543.5
May 202231.841.8
Jun 20223035
Jul 202229.234.8
Aug 202230.536
Sep 20223432.5
Oct 202238.230.8
Nov 202236.2534.25
Dec 20223833.75
Jan 202335.435.4
Feb 202337.2537.5
Mar 202335.7541.75
Apr 202333.435.6
May 20233033
Jun 20232733.25
Jul 20232631.4
Aug 202325.526.25
Sep 20232428.25
Oct 202323.627.8
Nov 202324.2524
Dec 202325.824
Jan 202424.7523.25
Feb 202425.521.75
Mar 202426.426.2
Apr 202429.532.1
May 202432.7529.9
Jun 202440.6525.65
Jul 202440.126.3
Aug 20243329.6
Sep 202421.9540.25
Oct 20241943
Nov 202418.543
Dec 202421.445.4

pCPA timelines

  • Median time under consideration, active negotiation time and total timelines have improved between 2020 and 2024.
  • The typical total negotiation time was 8 months from HTA recommendation to file completion.
Data for combination chart: Time under consideration* 
pCPA initiation yearMedian months
to pCPA milestones		Files meeting brand
process guideline target (%)
20163.3436.0%
20174.3725.0%
20183.7522.6%
20191.8457.1%
20205.0622.0%
20213.8120.3%
20224.4119.2%
20234.0425.9%
20243.5827.5%
Data for combination chart: Active negotiation time 
pCPA initiation yearMedian months to
pCPA milestones		Files meeting brand
process guideline target (%)
20168.2219.7%
20176.4425.0%
20185.1834.8%
20195.6920.0%
20205.4929.5%
20214.3142.0%
20223.4852.1%
20233.9147.1%
20243.3555.9%
Data for combination chart:  Total time* 
pCPA initiation yearMedian months to
pCPA milestones		Files meeting brand
process guideline target (%)
201611.8411.3%
201712.0512.5%
20189.2117.0%
20198.0234.7%
202010.9314.0%
20219.8322.0%
20229.6721.9%
20239.1724.1%
20248.3535.0%

* Time under consideration and total timelines are only assessed for files arising from HTA recommendations, and excludes files which do not undergo negotiations. pCPA targets outlined in the brand process guidelines are approximately two months for file engagement, four months for active negotiations and six months combined.